BCL2L1 and melanoma: Using the ELISPOT it has previously been demonstrated that breast cancer patients, melanoma patients and pancreatic cancer patients host spontaneous HLA class I-restricted CD8 T-cell responses specifically against 9–10 amino acid long Bcl-X(L)-derived peptides [7].